Cardiff Oncology, Inc. Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented At Asco 2025

Published: 2025-06-02 17:05:27 ET CRDF

Published on 06/02/2025 at 17:05

Cardiff Oncology, Inc. announced positive data from an investigator-initiated Phase 1b clinical trial evaluating onvansertib in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC) at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30-June 3, 2025, in Chicago, Illinois. Key highlights from the poster presentation: Phase 1b Study of PLK1 Inhibitor Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Patients (mTNBC); This trial was led by Antonio Giordano, MD, PhD at Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School. The objective of this dose escalation study was to evaluate the safety, pharmacokinetics, and pharmacodynamics of the combination of onvansertib and paclitaxel, a potential new drug combination for the treatment of mTNBC.

These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's current expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations, strategy, plans or intentions". These forward-looking statements arebased on Cardiff Oncology's currently expectations and actual results could differ materially.

There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of product candidate; results of preclinical studies or clinical trials for its product candidate could be unfavorable or delayed; need for additional financing; risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on information technology infrastructure, which could seriously harm financial condition and increase costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that product candidate will be utilized or prove to be commercially successful.

Additionally, there are no guarantees that future clinical trials will be completed or successful or that the company will be completed or successful.